The history of Sildenafil presents a interesting case for stakeholders in the medicinal sector. While initially a blockbuster success, producing huge profits, the patent expiration and the subsequent arrival of off-brand versions have considerably affected income. This raises questions about the long-term viability of related therapeutic innovation